TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (≥ 18 years)~* HIV-1 infection, clinical stability, and treatment with ATRIPLA ® for the past two years.~* Standard plasma viral load below the limit of detection for at least 2 years.~* CD4 count above 350/mm3 at the time of the consideration for the study.~* Negative pregnancy test in women of childbearing age, and commitment acceptable contraceptive use for at least 2 weeks before day 1 and until at least 6 months after the last dose of study drug.~* Patients should be given written informed consent~* In the opinion of the investigator, be able to follow the design of the protocol visits~Exclusion Criteria:~* Patients who have experienced virologic failure prior to any antiretroviral regimen~* Evidence of previous mutations versus efavirenz, tenofovir and emtricitabine~* Use of any other chronic treatment plus ATRIPLA has been introduced in the 6 months prior to entry of the patient in the study~* Any contraindication to study drug~* Any condition not ensure proper adherence to the study at the discretion of the attending physician of the patient~* Uncontrolled preexisting psychiatric illness~* Any current sign of alcoholism or other drug use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ATRIPLA three times a week. (Type: EXPERIMENTAL): Atripla (600 mg/200 mg/245 mg) three times a week.
- ATRIPLA one time a day. (Type: ACTIVE_COMPARATOR): Atripla (600 mg/200 mg/245 mg) one time a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Long-term Use of Valsartan in Children 6 Months to 5 Years Old With Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria~* Participants who qualified and entered the core study.~* Participants who participated in the core study, completed Period 1 and were re-randomized in Period 2 and continued for at least 3 days in Period 2.~Exclusion criteria~* Participants who did not complete Period 1 of the core study.~* Participants who were re-randomized in Period 2 of core study but did not continue for =\> 3 days in Period 2 of the core study.~* Participants who experienced any adverse events considered serious or drug related in the core study.~* Participants excluded from the core study.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Valsartan Open Label (Type: EXPERIMENTAL): Extemporaneous oral suspension prepared from valsartan tablets was administered to participants once daily. The starting dose of valsartan was 1 mg/kg, escalated to 2 mg/kg or 4 mg/kg based on mean sitting systolic blood pressure (MSSBP) control after 2 weeks up to 18 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of a Vibratory Stimulus on Mitigating Nociception-specific Responses to Skin Puncture in Neonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Neonatal Intensive Care Unit patient~* Between 36 to 56 weeks post-menstrual age~* Medically stable~* Due to have a clinically required bedside heel stick as part of their routine care~Exclusion Criteria:~* Congenital anomalies or abnormalities affecting the brain~* Patient is over 4 months corrected age~* Infants who receive analgesics or sedatives within 72 hours prior to assessment~* Administration of maternal analgesics or sedatives to which the infant may be exposed

- Gender: ALL
- Minimum Age: 36 Weeks
- Maximum Age: 56 Weeks
- Healthy Volunteers: t

Study Arms:
- No vibratory stimulus before or during heel lance (Type: NO_INTERVENTION): Baseline measurements and readings after vibration alone will be done, but no vibratory stimulus will be provided immediately preceding or during heel lance.
- Vibratory stimulus before and during heel lance (Type: EXPERIMENTAL): Baseline measurements and readings after vibration alone will be done, as well as a vibratory stimulus that will be provided immediately preceding and during heel lance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Combined With Hydromorphone in Tonsillectomy and Adenoidectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* experienced tonsillectomy and adenoidectomy~* ASA physical status I-II~* weight 12-30 kg~Exclusion Criteria:~* respiratory disease~* circulatory or nervous system disease~* hepatic dysfunction~* known adverse reactions to hydromophine and dexmedetomidine

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 10 Years
- Healthy Volunteers: t

Study Arms:
- group A (Type: EXPERIMENTAL): Dexmedetomidine(0.5 μg／kg)/hydromophine-based general anesthesia
- group B (Type: EXPERIMENTAL): Dexmedetomidine(1μg／kg)/hydromophine-based general anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age greater than 18 years old~* ST-segment elevation myocardial infarction~* Referred for primary PCI either within 12 h of symptom onset or between 12 and 24 h after onset with evidence of continuing ischemia~Exclusion Criteria:~* Unconsciousness~* Other conditions that make the patient incapable receiving integer loading dose of prasugrel~* Any contraindication and/or known hypersensitivity or allergy to aspirin, prasugrel, intravenous unfractionated heparin, cangrelor, tirofiban~* Any contraindication to primary PCI~* Administration of glycoprotein IIb/IIIa inhibitors (GPI) or P2Y12-inhibitors or cangrelor \< 7 days~* Chronic dialysis~* Recent (\< 15 days) or current major bleeding~* Recent (\< 15 days) major surgery~* Administration of fibrinolytics \< 30 days~* Current use or indication to oral anticoagulant~* Previous stroke or transient ischemic attack (TIA)~* Inability to follow the procedures of the study (language problems, psychological disorders, dementia) or comorbidities associated with less than 6 months survival (active malignancies drug or alcohol abuse, etc.)~* Women who are pregnant or breast feeding or with potential to become pregnant during the course of the study (age \< 55 years and last menstruation within the last 12 months) and did not undergo tubal ligation, ovariectomy or hysterectomy~* Participation in another study with investigational drug within the 30 days preceding and during the present study~* Enrolment of the investigator, his/her family members, employees and other dependent persons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cangrelor (Type: EXPERIMENTAL): Cangrelor bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI).
- Tirofiban (Type: ACTIVE_COMPARATOR): Tirofiban bolus of 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance \< 60 ml/min).
- Prasugrel (Type: ACTIVE_COMPARATOR): Prasugrel oral integer or chewed at an identical loading dose of 60 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Male and/or female participant, between 18 and 55 years of age, inclusive. Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 30.0 kg/m2, inclusive.~Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).~Having given written informed consent prior to undertaking any study-related procedure.~Not under any administrative or legal supervision or under institutionalization due to regulatory or juridical order.~Exclusion Criteria:~Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteo-muscular, articular, psychiatric, systemic, ocular, gynecologic (if female), or infectious disease, or signs of acute illness.~Personal medical history of seizure.~Frequent headaches and/or migraine, recurrent nausea and/or vomiting (for vomiting only: more than twice a month).~Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication, with the exception of hormonal contraception or menopausal hormone replacement therapy; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion.~Positive result for hepatitis B, C or HIV~Positive result on urine drug screen~Positive alcohol test.~Any consumption of citrus fruits or their juices within 5 days before inclusion.~Current psychiatric disorder, suicidal ideation in the previous 6 months (as assessed by the C-SSRS), or a lifetime suicide attempt.~Additional exclusion criteria applied, and specially for Part 1b, criteria related to the study procedure of lumbar puncture.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- SAR443820 (Type: EXPERIMENTAL): Single dose oral ascending dose (parts 1a and 1b) and multiple ascending oral dose (part 2) of SAR443820
- Placebo (Type: PLACEBO_COMPARATOR): Single dose oral ascending dose (part 1a) and multiple ascending oral dose (part 2) of matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Study of Vitamin D Deficiency in Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age 13-20~Exclusion Criteria:~* currently receiving treatment for hypovitaminosis D~* hepatic or renal disease~* metabolic rickets~* inability to complete the questionnaire

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 20 Years
- Healthy Volunteers: t

Study Arms:
- Low Dose (Type: EXPERIMENTAL): VItamin D3 1,000 IU~1 x day, 8 weeks
- Weekly High Dose (Type: EXPERIMENTAL): Vitamin D3 50,000 IU~1x week, 8 weeks
- Daily High Dose (Type: EXPERIMENTAL): Vitamin D3 5,000 IU~1x day, 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Adults with end stage renal disease who are receiving a stable hemodialysis regimen (3 times per week) with sufficient dialysis adequacy;~* Serum phosphorus level range from \>1.94 mmol/L (6.0 mg/dL) to ≤3.23 mmol/L (10.0 mg/dL) at the end of washout phase.~Exclusion Criteria:~* Kidney transplant patient or scheduled kidney transplant, or change to peritoneal dialysis, home hemodialysis or plan to relocate to another dialysis center during the study period；~* Serum phosphorus level is \<1.29 mmol/L（4.0 mg/dL) or \>2.42 mmol/L（7.5 mg/dL) at screening, or documented to be \>3.23 mmol/L（10 mg/dL) within the latest three month prior to screening (screening included);~* Serum calcium level is \<8 mg/dL or \>11 mg/dL at the screening;~* Serum immunoreactive parathyroid hormone (iPTH)\>1000 pg/mL at the screening;~* History of hemochromatosis or serum ferritin value ≥1000 μg/L at screening；~* Current clinically significant gastrointestinal (GI) disorder, or history of intestine obstruction, gastrectomy or duodenectomy, or GI tract surgery within 12 weeks prior to screening;~* Poorly controlled hypertension, cardiovascular disorders, and history of cerebrovascular disease or cardiovascular disease event within 24 weeks (6 months) prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VS-505 500mg (Type: EXPERIMENTAL): VS-505 500mg (two 250 mg capsules) oral administration three times a day with meal, daily total dosage 1500mg.
- VS-505 750mg (Type: EXPERIMENTAL): VS-505 750mg (one 750 mg capsule) oral administration three times a day with meal, daily total dosage 2250mg.
- VS-505 1500mg (Type: EXPERIMENTAL): VS-505 1500mg (two 750 mg capsules) oral administration three times a day with meal, daily total dosage 4500mg.
- VS-505 2250mg (Type: EXPERIMENTAL): VS-505 2250mg (three 750 mg capsules) oral administration three times a day with meal, daily total dosage 6750mg.
- Sevelamer Carbonate 1600mg (Type: ACTIVE_COMPARATOR): Sevelamer Carbonate 1600mg (two 800mg pills) oral administration three times a day with meal, daily total dosage 4800mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Study to Assess Efficacy and Safety of 4 Doses of LAS100977 in Chronic Obstructive Pulmonary Disease (COPD) Population

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and non-pregnant, non-lactating females aged 40 or older.~2. Patients with a clinical diagnosis of COPD, according to the GOLD guidelines and stable airway obstruction.~3. Patients with a post-salbutamol FEV1 equal to or greater than 30% of the predicted value and less than 80% of the predicted value~4. Post-salbutamol FEV1/FVC \< 70% at screening visit.~5. Pre-dose FEV1 value of first treatment period within the range of 80-120% of the FEV1 measured at screening prior to salbutamol inhalation.~6. Current, or ex-cigarette smokers (former) with a smoking history of at least 10 pack-years.~7. Patients whose COPD symptoms at the time of randomisation are stable compared to the Screening visit, according to the investigator's medical judgment.~Exclusion Criteria:~1. History or current diagnosis of asthma.~2. A respiratory tract infection or COPD exacerbation in the six weeks prior to the screening visit.~3. Patients who have been hospitalised for an acute COPD exacerbation in the 3 months prior to screening visit.~4. Clinically significant respiratory conditions other than COPD condition.~5. Clinically significant cardiovascular conditions.~6. Patients unable to properly use a dry powder or pMDI inhaler device or unable to perform acceptable spirometry.~7. Clinically relevant abnormalities laboratory, ECG parameters or physical examination results at the screening evaluation that in the investigator's opinion, preclude study participation.~8. Patients who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required washout period for a particular prohibited medication.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm #2 (Type: EXPERIMENTAL): Single dose, double blind treatment period
- Arm #3 (Type: EXPERIMENTAL): Single dose, double blind treatment period
- Arm #4 (Type: EXPERIMENTAL): Single dose, double blind treatment period
- Arm #5 (Type: ACTIVE_COMPARATOR): Single dose, double blind treatment period
- Arm #6 (Type: PLACEBO_COMPARATOR): Single dose, double blind treatment period
- Arm #1 (Type: EXPERIMENTAL): Single dose, double blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iduronate-2-sulfatase Enzyme Replacement Therapy in Mucopolysaccharidosis II (MPS II)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible to participate in this study, patients must meet the following inclusion criteria prior to enrollment:~1. The diagnosis of MPS II will be determined by the investigator based upon both clinical and biochemical criteria.~2. All patients must have at least one of the following Clinical Criteria considered by the investigator to be MPS II-related:~   * Hepatosplenomegaly~  * Radiographic evidence of dysostosis multiplex~  * Valvular heart disease~  * Evidence of obstructive pulmonary disease~3. In addition, patients must have the following Biochemical Criteria:~   * Documented deficiency in iduronate-2-sulfastase enzyme activity of less than or equal to 10% of the lower limit of the normal range as measured in plasma, fibroblasts, or leukocytes (based on normal range of measuring laboratory).~  * A normal enzyme activity level of one other sulfatase as measured in plasma, fibroblasts, or leukocytes (based on normal range of measuring laboratory).~4. Must be male, 5 to 25 years of age.~5. Forced vital capacity of \<80% of predicted obtained at the baseline evaluation of this study.~6. Must be able to adequately perform the testing required in this study, including reproducible pulmonary function testing by spirometry, as judged by the investigator.~7. Patient, patient's parent(s), or legally authorized guardian must have voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent form after all relevant aspects of the study have been explained and discussed with the patient.~Exclusion Criteria:~Patients meeting any of the following criteria are not eligible for participation in this study:~1. Patient has received treatment with another investigational therapy within the past 60 days.~2. Patient, patient's parent(s), or patient's legal guardian is unable to understand the nature, scope, and possible consequences of the study.~3. Patient is unable to comply with the protocol (e.g., due to a medical condition such as cervical cord compression or uncooperative attitude) or is unlikely to complete the study, as determined by the investigator.~4. Patient has a tracheostomy.~5. Patient has received a bone marrow or cord blood transplant.~6. Patient with known hypersensitivity to any of the components of iduronate-2-sulfatase.

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: 25 Years
- Healthy Volunteers: f

Study Arms:
- Idursulfase weekly (0.5 mg/kg) (Type: EXPERIMENTAL): None
- Idursulfase every other week (0.5 mg/kg) (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 18 to 65 years who present to the GI clinic for an EGD or colonoscopy~Exclusion Criteria:~* Poor vital sign stability~* Hypoxia: O2 \< 92%,~* Hypotension, hypertension, heart rate and respiratory rates greater than 20% above or below normal as dictated by normal ranges in SAMMC protocol~* Any allergy to ketamine, fentanyl, or midazolam~* Patient is pregnant or refuses pregnancy test, in women of child-bearing potential.\*~* American Society of Anesthesiologists (ASA) score\>3~* Presence of a history of psychosis, hallucinations, and/or a psychotic disorder~* History of increased intracranial pressure/ hypertensive hydrocephalus within the last 3 months~* Active pulmonary infection or disease.~* History of airway instability, tracheal surgery, or tracheal stenosis.~  * \* Not applicable if patient is a female over 50 years old or has had a hysterectomy and/or oophorectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Ketamine (Type: EXPERIMENTAL): Group will receive ketamine 0.5-1mg/kg for a loading dose then subsequent IV pushes of 10-20mg for maintenance. 1mg IV of midazolam will be administered prior to ketamine for anxiolysis and to help minimize emergence reaction.
- Control (Type: ACTIVE_COMPARATOR): This group will receive midazolam and fentanyl alternated as currently preformed for endoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete